Achillion Pharmaceuticals (ACHN) Coverage Initiated at B. Riley

B. Riley began coverage on shares of Achillion Pharmaceuticals (NASDAQ:ACHN) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage issued a neutral rating and a $3.50 price objective on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the company. BidaskClub raised Achillion Pharmaceuticals from a strong sell rating to a sell rating in a research note on Monday. Zacks Investment Research raised Achillion Pharmaceuticals from a hold rating to a buy rating and set a $4.50 target price for the company in a research note on Monday, November 6th. Finally, Leerink Swann reissued a buy rating and set a $5.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $4.89.

Achillion Pharmaceuticals (ACHN) traded down $0.03 during mid-day trading on Thursday, reaching $2.82. The company had a trading volume of 1,225,568 shares, compared to its average volume of 1,716,912. The firm has a market capitalization of $386.00, a P/E ratio of -5.71 and a beta of 1.32. Achillion Pharmaceuticals has a fifty-two week low of $2.58 and a fifty-two week high of $5.66.

In other Achillion Pharmaceuticals news, major shareholder & Johnson Johnson sold 18,367,346 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $2.75, for a total transaction of $50,510,201.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.24% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in the company. Swiss National Bank grew its holdings in shares of Achillion Pharmaceuticals by 19.1% during the fourth quarter. Swiss National Bank now owns 189,800 shares of the biopharmaceutical company’s stock worth $547,000 after purchasing an additional 30,400 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Achillion Pharmaceuticals during the fourth quarter worth about $109,000. Bourgeon Capital Management LLC grew its holdings in shares of Achillion Pharmaceuticals by 64.4% during the fourth quarter. Bourgeon Capital Management LLC now owns 48,504 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 19,004 shares during the last quarter. Matisse Capital grew its holdings in shares of Achillion Pharmaceuticals by 15.8% during the fourth quarter. Matisse Capital now owns 135,445 shares of the biopharmaceutical company’s stock worth $390,000 after purchasing an additional 18,500 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Achillion Pharmaceuticals by 4.5% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 549,189 shares of the biopharmaceutical company’s stock worth $1,582,000 after purchasing an additional 23,577 shares during the last quarter. Institutional investors own 76.78% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2018/02/09/achillion-pharmaceuticals-achn-coverage-initiated-at-b-riley.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit